London — Novo Nordisk trimmed its full-year profit outlook Wednesday after reporting weaker-than-expected quarterly sales of its popular weight loss drug Wegovy. The results end a prolonged streak of positive earnings news from the first mover in the obesity drug race, which has seen its market value …